Alison Bozung, OD
Optometry · Coral Gables
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · University of Miami · 2,346 clinicians in this group
Hospitals listed: Univ of Miami Hospital and Clinics-Sylvester Compr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bozung’s office at (305) 689-8648 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$9,857
Medicare paid this office $9,857 for 161 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Emergency department visit with low level of medical decision making | 65 | $3,381 | $51 |
| Short return visit (20+ min) | 25 | $1,730 | $44 |
| Emergency department visit with moderate level of medical decision making | 11 | $1,025 | $93 |
| Established patient complete exam of visual system | 14 | $601 | $43 |
| New patient visit (15+ min) | 15 | $563 | $38 |
See all 6 services
| Emergency department visit with low level of medical decision making | 65 | $3,381 | $51 |
| Short return visit (20+ min) | 25 | $1,730 | $44 |
| Emergency department visit with moderate level of medical decision making | 11 | $1,025 | $93 |
| Established patient complete exam of visual system | 14 | $601 | $43 |
| New patient visit (15+ min) | 15 | $563 | $38 |
| Imaging of optic nerve | 15 | $238 | $14 |
Who their Medicare patients are
161 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 11% · Women 54% · Also on Medicaid 39% · Health risk score 1.53. Sicker patients than 9 in 10 peers; the typical optometry clinician is at 0.97.
Conditions among them: High blood pressure 75% · Diabetes 33% · Depression 30% · Coronary heart disease 29% · Chronic kidney disease 28% · Cancer 22% · COPD 18% · Atrial fibrillation 17% · Heart failure 16% · Stroke 12% · Dementia 8%.
The office billed $57,150, Medicare allowed $15,098 and paid $9,857; for 239 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 161 | 239 | 73 | 1.53 | $57,150 | $9,857 |
| 2023 | 145 | 193 | 74 | 1.19 | $42,431 | $8,013 |
| 2022 | 193 | 260 | 73 | 1.74 | $58,155 | $11,536 |
| 2021 | 281 | 332 | 74 | 1.56 | $80,968 | $19,051 |
| 2020 | 201 | 240 | 73 | 1.63 | $56,558 | $12,782 |
| 2019 | 548 | 849 | 72 | 1.43 | $198,349 | $28,019 |
| 2018 | 653 | 1,282 | 71 | 1.28 | $297,201 | $43,810 |
| 2017 | 341 | 563 | 71 | 1.38 | $142,192 | $21,173 |
| 2016 | 53 | 70 | 67 | 1.13 | $16,709 | $2,855 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Emergency department visit with low level of medical decision making | 56 | $2,750 | $49 |
| Short return visit (20+ min) | 14 | $1,090 | $50 |
| Established patient complete exam of visual system | 20 | $879 | $44 |
| New patient visit (15+ min) | 20 | $505 | $25 |
| Imaging of optic nerve | 12 | $176 | $14 |
2022: 7 services
| Emergency department visit with low level of medical decision making | 97 | $5,393 | $56 |
| Short return visit (20+ min) | 23 | $1,617 | $51 |
| Emergency department visit with moderate level of medical decision making | 12 | $932 | $78 |
| Established patient complete exam of visual system | 19 | $764 | $40 |
| New patient visit (15+ min) | 24 | $717 | $30 |
| Imaging of retina | 14 | $206 | $15 |
| Imaging of optic nerve | 13 | $178 | $13 |
2021: 10 services
| Emergency department visit with low level of medical decision making | 136 | $7,476 | $55 |
| New patient complete exam of visual system | 13 | $1,430 | $110 |
| Short return visit (20+ min) | 22 | $1,424 | $55 |
| Short return visit (20+ min) | 21 | $1,321 | $63 |
| Established patient complete exam of visual system | 13 | $1,227 | $94 |
| New patient visit (30+ min) | 16 | $1,073 | $67 |
| New patient visit (30+ min) | 14 | $1,064 | $76 |
| Established patient complete exam of visual system | 15 | $910 | $61 |
| New patient visit (15+ min) | 14 | $576 | $41 |
| Imaging of retina | 13 | $396 | $28 |
2020: 4 services
| Emergency department visit with low level of medical decision making | 114 | $6,592 | $57 |
| New patient visit (30+ min) | 22 | $1,489 | $68 |
| Short return visit (20+ min) | 18 | $926 | $42 |
| Short return visit (20+ min) | 11 | $548 | $46 |
2019: 13 services
| Short return visit (20+ min) | 208 | $7,579 | $30 |
| Emergency department visit with low level of medical decision making | 125 | $6,917 | $54 |
| New patient visit (30+ min) | 109 | $3,878 | $36 |
| Established patient complete exam of visual system | 43 | $2,380 | $55 |
| New patient complete exam of visual system | 32 | $2,154 | $67 |
| Established patient complete exam of visual system | 12 | $817 | $68 |
| Return visit (30+ min) | 13 | $655 | $50 |
| Imaging of retina | 35 | $587 | $17 |
| Ultrasound scan of cornea to determine thickness | 89 | $347 | $4 |
| Ct scan of cornea | 29 | $315 | $10 |
| Imaging of optic nerve | 23 | $309 | $13 |
| Exam of visual field with extended testing | 20 | $300 | $15 |
| Imaging of front third of eye using a special microscope | 14 | $156 | $11 |
2018: 15 services
| Short return visit (20+ min) | 235 | $11,714 | $36 |
| New patient complete exam of visual system | 133 | $8,395 | $63 |
| New patient visit (30+ min) | 161 | $8,177 | $51 |
| Established patient complete exam of visual system | 54 | $2,763 | $50 |
| New patient visit (15+ min) | 79 | $2,745 | $35 |
| Return visit (30+ min) | 25 | $1,252 | $50 |
| Ultrasound scan of cornea to determine thickness | 174 | $1,249 | $7 |
| New patient visit (45+ min) | 16 | $1,169 | $73 |
| Imaging of retina | 49 | $1,000 | $19 |
| Ct scan of cornea | 67 | $938 | $14 |
| Exam of visual field with extended testing | 39 | $856 | $19 |
| New patient problem focused exam of visual system | 27 | $808 | $30 |
| Imaging of optic nerve | 40 | $611 | $15 |
| Imaging of front third of eye using a special microscope | 30 | $495 | $16 |
| Established patient problem focused exam of visual system | 11 | $362 | $33 |
2017: 11 services
| Short return visit (20+ min) | 93 | $4,901 | $36 |
| New patient visit (30+ min) | 97 | $4,630 | $48 |
| New patient complete exam of visual system | 48 | $3,311 | $69 |
| New patient visit (15+ min) | 84 | $2,658 | $32 |
| Established patient complete exam of visual system | 24 | $1,268 | $53 |
| Return visit (30+ min) | 19 | $1,141 | $54 |
| New patient problem focused exam of visual system | 21 | $622 | $30 |
| Imaging of retina | 23 | $275 | $12 |
| Ultrasound scan of cornea to determine thickness | 38 | $268 | $7 |
| Imaging of optic nerve | 13 | $173 | $13 |
| Ct scan of cornea | 13 | $156 | $11 |
2016: 2 services
| New patient visit (30+ min) | 12 | $684 | $57 |
| New patient visit (15+ min) | 15 | $563 | $38 |
Medicaid work
$21,672 in 2024
Medicaid paid $21,672 for 371 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 277 | $18,399 |
| EMERGENCY DEPT VISIT LOW MDM | 94 | $3,274 |
| 2024 | 371 | 2 | 38 | $21,672 |
| 2023 | 289 | 2 | 32 | $17,396 |
| 2022 | 540 | 2 | 34 | $26,193 |
| 2021 | 669 | 2 | 35 | $29,539 |
| 2020 | 169 | 1 | 32 | $3,017 |
| 2019 | 515 | 5 | 42 | $18,707 |
| 2018 | 564 | 5 | 44 | $35,795 |
See the largest Medicaid services in earlier years
2023
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 178 | $13,120 |
| EMERGENCY DEPT VISIT LOW MDM | 111 | $4,276 |
2022
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 305 | $18,594 |
| EMERGENCY DEPT VISIT LOW MDM | 235 | $7,599 |
2021
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 365 | $21,674 |
| EMERGENCY DEPT VISIT LOW MDM | 304 | $7,865 |
2020
| EMERGENCY DEPT VISIT LOW MDM | 169 | $3,017 |
2019
| Hospital outpatient clinic visit for assessment and management of a patient | 149 | $11,564 |
| EMERGENCY DEPT VISIT LOW MDM | 258 | $4,941 |
| Short return visit (20+ min) | 81 | $1,531 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 14 | $521 |
| DETERMINATION REFRACTIVE STATE | 13 | $151 |
2018
| Hospital outpatient clinic visit for assessment and management of a patient | 400 | $32,186 |
| Short return visit (20+ min) | 78 | $1,295 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 27 | $1,178 |
| DETERMINATION REFRACTIVE STATE | 46 | $632 |
| New patient visit (30+ min) | 13 | $505 |
Drugs they prescribed that Part D paid
$14,403
Pharmacies billed $14,403 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 319) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
228 generic and 91 brand-name prescriptions · $14,403 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brimonidine Tartrate-Timolol | 17 | $1,294 | $76 |
| Prednisolone Acetate | 15 | $583 | $39 |
| Dorzolamide-Timolol | 43 | $522 | $12 |
| Latanoprost | 70 | $449 | $6 |
| Moxifloxacin | 15 | $322 | $21 |
See all 9 drugs
| Brimonidine Tartrate-Timolol | 17 | $1,294 | $76 |
| Prednisolone Acetate | 15 | $583 | $39 |
| Dorzolamide-Timolol | 43 | $522 | $12 |
| Latanoprost | 70 | $449 | $6 |
| Moxifloxacin | 15 | $322 | $21 |
| Neomycin-Polymyxin-Dexameth | 24 | $287 | $12 |
| Timolol Maleate | 21 | $188 | $9 |
| Erythromycin | 12 | $114 | $10 |
| Brimonidine | 23 | $99 | $4 |
Year by year
| 2024 | 319 | 120 | 0% (0) | 29% | $14,403 |
| 2023 | 256 | 119 | 0% (0) | 36% | $16,110 |
| 2022 | 305 | 141 | 0% (0) | 34% | $14,227 |
| 2021 | 274 | 140 | 0% (0) | 34% | $23,777 |
| 2020 | 472 | 191 | 0% (0) | 34% | $35,510 |
| 2019 | 1,433 | 373 | 0% (0) | 44% | $107,105 |
| 2018 | 735 | 236 | 0% (0) | 43% | $47,441 |
| 2017 | 202 | 78 | 0% (0) | 38% | $14,049 |
| 2016 | 14 | 13 | 0% (0) | None | $484 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Prednisolone Acetate | 27 | $1,045 | $39 |
| Latanoprost | 55 | $970 | $18 |
| Neomycin-Polymyxin-Dexameth | 27 | $341 | $13 |
| Dorzolamide-Timolol | 20 | $300 | $15 |
| Timolol Maleate | 22 | $192 | $9 |
| Erythromycin | 15 | $181 | $12 |
2022: 10 drugs
| Latanoprost | 74 | $1,543 | $21 |
| Prednisolone Acetate | 30 | $1,282 | $43 |
| Fluorometholone | 14 | $965 | $69 |
| Dorzolamide-Timolol | 22 | $752 | $34 |
| Acyclovir | 11 | $431 | $39 |
| Neomycin-Polymyxin-Dexameth | 22 | $343 | $16 |
| Valacyclovir | 13 | $327 | $25 |
| Erythromycin | 16 | $179 | $11 |
| Polymyxin B Sul-Trimethoprim | 23 | $151 | $7 |
| Timolol Maleate | 15 | $119 | $8 |
2021: 10 drugs
| Restasis Multidose | 11 | $10,184 | $926 |
| Combigan | 12 | $2,866 | $239 |
| Prednisolone Acetate | 27 | $1,489 | $55 |
| Dorzolamide-Timolol | 24 | $1,026 | $43 |
| Latanoprost | 29 | $575 | $20 |
| Doxycycline Hyclate | 12 | $289 | $24 |
| Neomycin-Polymyxin-Dexameth | 22 | $260 | $12 |
| Brimonidine | 20 | $204 | $10 |
| Erythromycin | 17 | $174 | $10 |
| Polymyxin B Sul-Trimethoprim | 19 | $171 | $9 |
2020: 10 drugs
| Prednisolone Acetate | 65 | $3,162 | $49 |
| Combigan | 11 | $3,038 | $276 |
| Fluorometholone | 24 | $2,347 | $98 |
| Latanoprost | 87 | $1,809 | $21 |
| Dorzolamide-Timolol | 50 | $1,728 | $35 |
| Doxycycline Hyclate | 25 | $748 | $30 |
| Valacyclovir | 18 | $559 | $31 |
| Timolol Maleate | 27 | $414 | $15 |
| Erythromycin | 24 | $361 | $15 |
| Brimonidine | 26 | $300 | $12 |
2019: 22 drugs
| Restasis | 24 | $14,736 | $614 |
| Fluorometholone | 123 | $13,775 | $112 |
| Prednisolone Acetate | 200 | $11,079 | $55 |
| Lotemax | 32 | $9,929 | $310 |
| Combigan | 37 | $8,423 | $228 |
| Doxycycline Hyclate | 120 | $6,941 | $58 |
| Alphagan P | 13 | $3,236 | $249 |
| Dorzolamide-Timolol | 80 | $3,095 | $39 |
| Valacyclovir | 60 | $2,830 | $47 |
| Latanoprost | 156 | $2,583 | $17 |
| Timolol Maleate | 70 | $2,525 | $36 |
| Simbrinza | 13 | $2,157 | $166 |
| Acyclovir | 86 | $1,641 | $19 |
| Brimonidine | 67 | $1,614 | $24 |
| Olopatadine | 33 | $1,473 | $45 |
| Medroxyprogesterone Acetate | 12 | $1,043 | $87 |
| Erythromycin | 66 | $1,026 | $16 |
| Minocycline | 38 | $694 | $18 |
| Doxycycline Monohydrate | 14 | $440 | $31 |
| Dorzolamide | 16 | $418 | $26 |
| Azithromycin | 22 | $417 | $19 |
| Polymyxin B Sul-Trimethoprim | 24 | $201 | $8 |
2018: 15 drugs
| Fluorometholone | 80 | $9,089 | $114 |
| Prednisolone Acetate | 125 | $7,953 | $64 |
| Valacyclovir | 69 | $3,202 | $46 |
| Doxycycline Hyclate | 86 | $2,557 | $30 |
| Olopatadine | 24 | $1,313 | $55 |
| Timolol Maleate | 37 | $1,027 | $28 |
| Acyclovir | 40 | $958 | $24 |
| Erythromycin | 33 | $414 | $13 |
| Dorzolamide-Timolol | 16 | $411 | $26 |
| Dorzolamide | 13 | $353 | $27 |
| Brimonidine | 31 | $346 | $11 |
| Cyclopentolate | 13 | $337 | $26 |
| Latanoprost | 31 | $336 | $11 |
| Neomycin-Polymyxin-Dexameth | 11 | $174 | $16 |
| Polymyxin B Sul-Trimethoprim | 12 | $114 | $10 |
2017: 6 drugs
| Prednisolone Acetate | 31 | $2,084 | $67 |
| Valacyclovir | 42 | $1,831 | $44 |
| Fluorometholone | 15 | $1,793 | $120 |
| Doxycycline Hyclate | 17 | $483 | $28 |
| Dorzolamide-Timolol | 12 | $273 | $23 |
| Polymyxin B Sul-Trimethoprim | 14 | $116 | $8 |
Money from drug and device companies
$5,878 in 2025
| 2025 | 4 | 13 | $5,200 | $5,878 |
| 2024 | 7 | 8 | $6,978 | $7,347 |
| 2023 | 3 | 5 | $750 | $951 |
| 2022 | 8 | 20 | $1,460 | $3,321 |
| 2021 | 4 | 5 | None | $458 |
| 2020 | 2 | 3 | None | $221 |
| 2019 | 4 | 11 | None | $1,807 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Tryptyr | $2,950 | 3 payments
|
| Alcon Research | Tryptyr | $2,400 | 1 payment
|
| Carl Zeiss Meditec USA | Cirrus Hd-Oct | $491 | 8 payments
|
| Mallinckrodt Hospital Products | Acthar | $37 | 1 payment
|
See all 13 published payments
| Mallinckrodt Hospital Products | Meals · 2025-09-26 | Acthar | $37 |
| Alcon Vision | Paid to speak or teach · 2025-05-08 | Tryptyr | $1,400 |
| Carl Zeiss Meditec USA | Travel · 2025-05-06 | Cirrus Hd-Oct | $58 |
| Carl Zeiss Meditec USA | Travel · 2025-04-05 | Cirrus Hd-Oct | $274 |
| Carl Zeiss Meditec USA | Meals · 2025-04-03 | Cirrus Hd-Oct | $139 |
| Carl Zeiss Meditec USA | Meals · 2025-04-02 | Cirrus Hd-Oct | $1 |
| Carl Zeiss Meditec USA | Meals · 2025-03-31 | Cirrus Hd-Oct | $1 |
| Carl Zeiss Meditec USA | Meals · 2025-03-30 | Cirrus Hd-Oct | $2 |
| Carl Zeiss Meditec USA | Meals · 2025-03-30 | Cirrus Hd-Oct | $3 |
| Carl Zeiss Meditec USA | Meals · 2025-03-29 | Cirrus Hd-Oct | $13 |
| Alcon Vision | Paid to speak or teach · 2025-03-07 | Tryptyr | $1,400 |
| Alcon Research | Consulting · 2025-02-20 | Tryptyr | $2,400 |
| Alcon Vision | Meals · 2025-02-18 | Tryptyr | $150 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,347
| Dompe US | None | $6,178 | 2 payments
|
| Alcon Research | None | $800 | 1 payment
|
| Bausch & Lomb Americas | Miebo | $109 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $91 | 1 payment
|
| Alcon Vision | None | $60 | 1 payment
|
| Abbvie | Lumigan | $56 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $53 | 1 payment
|
2023: $951
| Bausch & Lomb Americas | Miebo | $802 | 3 payments
|
| AbbVie | Lumigan | $124 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $24 | 1 payment
|
2022: $3,321
| Oyster Point Pharma | Tyrvaya | $1,434 | 6 payments
|
| Bausch & Lomb Americas | Vyzulta | $1,157 | 6 payments
|
| Sun Pharmaceutical Industries | Cequa | $211 | 2 payments
|
| Johnson & Johnson Vision Care | Acuvue | $144 | 1 payment
|
| Abbvie | Vuity | $122 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $118 | 1 payment
|
| Dompe US | Oxervate | $102 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $33 | 1 payment
|
2021: $458
| Novartis Pharmaceuticals | Xiidra | $198 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Stellaris | $125 | 1 payment
|
| Dompe US | Oxervate | $92 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $44 | 1 payment
|
2020: $221
| Allergan | Ozurdex | $180 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $41 | 1 payment
|
2019: $1,807
| Alcon Vision | Dailies | $1,451 | 6 payments
|
| Sight Sciences | Tearcare | $165 | 1 payment
|
| Shire North American Group | Xiidra | $140 | 3 payments
|
| Sun Pharmaceutical Industries | Cequa | $52 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1114302858
- Licence
- FL OPC5107
- Trained
- Southern College of Optometry, 2015
- Group
- University of Miami
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-07-23
- NPI last updated
- 2026-09-09
- NPI record certified
- 2026-09-09
This is when the NPI record was last certified, not a medical board exam.